Prothena Corporation plc

Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.

Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully acquired 50,000 shares of the company's stock in a transaction on Friday, October 23rd. The shares were acquired at an average price of $8.07 per share, for a total transaction of $403,500.00. Following the completion of the acquisition, the insider directly owned 1,187,000

Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 100,000 shares of the business's stock in a transaction that occurred on Thursday, October 22nd. The stock was bought at an average cost of $8.19 per share, with a total value of $819,000.00. Following the acquisition, the insider owned 1,137,000 shares in

Prothena Corporation plc (NASDAQ: PRTA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.26 and traded as low as $7.96. Prothena shares last traded at $8.25, with a volume of 381,828 shares traded. Analyst Ratings Changes A number of research

PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.

Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one

Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 125,000 shares of the business's stock in a transaction on Wednesday, October 7th. The stock was bought at an average cost of $8.40 per share, for a total transaction of $1,050,000.00. Following the purchase, the insider owned 439,000 shares of the company's

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?